HK2 and neuroblastoma: Combinational administration of EIP‐22 and glycolysis inhibitors (2‐DG or 3‐BP) targeting HK2, GPI, or GAPDH (Cardaci et al, 2012; Zhang et al, 2014) exerts synergistic effects in suppressing growth and aggressiveness of NB cells.